Business Context and Reporting Period
This Form 8-K was filed by SRx Health Solutions, Inc. (formerly Better Choice Company, Inc.) on September 15, 2025. The filing primarily addresses a change in the company's independent registered public accounting firm and provides updates on ongoing creditor protection proceedings for its Canadian subsidiary, SRx Canada.
Key Financial Metrics and Status
The filing does not provide current revenue, profit, cash flow, or liquidity figures for the period ending September 15, 2025. However, it discloses the following financial context:
- Revenue Error: An overstatement of revenue of approximately USD 1.8 million was identified for the fiscal year ended September 30, 2024, related to prescriptions billed without meeting performance obligations.
- Going Concern: Previous audit reports for SRx Canada (fiscal years 2023 and 2024) and Better Choice Company, Inc. (fiscal year 2024) included explanatory paragraphs raising substantial doubt about the entities' ability to continue as a going concern.
- Asset Sales: As of September 15, 2025, the majority of SRx Canada's assets have been sold through court-approved transactions under the Companies' Creditors Arrangement Act (CCAA), with closings expected in the coming weeks.
Material Changes and Accounting Firm Transition
On September 15, 2025, the company dismissed CBIZ CPAs P.C. as its independent auditor and engaged Davidson and Company LLP for the fiscal year ending September 30, 2025. This change follows a reverse acquisition merger completed on April 24, 2025, with SRx Health Solutions (Canada), Inc.
Material weaknesses in internal controls were previously identified by both the former U.S. auditor (Marcum LLP) and the former Canadian auditor (MNP LLP), including:
- Ineffective revenue recognition controls and IT general control deficiencies.
- Management override of controls, including redirection of employer RRSP payments by a former CFO.
- Lack of documentation for retail pharmacy sales and debt agreements.
- Inadequate segregation of duties and insufficient technical accounting analyses.
Outlook, Risks, and Contingencies
Financial Statement Revision: Management concluded the USD 1.8 million revenue error was not material to previously issued audited statements. The company plans to revise, rather than restate, the fiscal year 2024 financial statements in its upcoming Form 10-Q for the period ended June 30, 2025. An additional material weakness related to revenue recognition is expected.
Legal Proceedings: SRx Canada remains under CCAA protection in the Ontario Superior Court of Justice. The Monitor, Grant Thornton Limited, is overseeing the asset sales.
Risks: The company faces significant risks related to its history of material weaknesses in internal controls, ongoing liquidity concerns evidenced by the CCAA proceedings, and the potential for further financial statement adjustments.
Investor Verification Checklist
- Verify the status and expected closing dates of the CCAA asset sales for SRx Canada via the Grant Thornton Monitor website.
- Review the upcoming Form 10-Q (period ended June 30, 2025) for the revised fiscal year 2024 financial statements reflecting the USD 1.8 million revenue adjustment.
- Assess the new auditor's (Davidson and Company LLP) initial findings regarding the company's internal controls and going concern status.
- Monitor for any further disclosures regarding the resolution of material weaknesses in revenue recognition and IT controls.